Skip to content
10-Q

Quarterly Report

Gene Biotherapeutics, Inc.

0001493152-21-021992

← back to feed
Filed
Sep 3, 2021 12:00 AM ET
Period of report

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2020 · Aug 28, 2021 64.93M sh
Operating Cash Flow Q1 2020 · Mar 31, 2020 −$93.86K
Operating Cash Flow Q1 2020 · Mar 31, 2019 −$40.34K
Cash And Equivalents Q1 2020 · Mar 31, 2020 $2.93K
Cash And Equivalents Q1 2020 · Dec 31, 2019 $400
Stockholders Equity Q1 2020 · Mar 31, 2020 −$4.44M
Stockholders Equity Q1 2020 · Dec 31, 2019 −$4.29M
Current Liabilities Q1 2020 · Mar 31, 2020 $4.9M
Current Liabilities Q1 2020 · Dec 31, 2019 $4.76M
Total Liabilities Q1 2020 · Mar 31, 2020 $5.15M
Total Liabilities Q1 2020 · Dec 31, 2019 $4.89M
Current Assets Q1 2020 · Mar 31, 2020 $114.91K
Current Assets Q1 2020 · Dec 31, 2019 $32.8K
Total Assets Q1 2020 · Mar 31, 2020 $129.67K
Total Assets Q1 2020 · Dec 31, 2019 $35.44K
Sga Expense Q1 2020 · Mar 31, 2020 $106.28K
Sga Expense Q1 2020 · Mar 31, 2019 $179.6K
Rd Expense Q1 2020 · Mar 31, 2020 $46.61K
Rd Expense Q1 2020 · Mar 31, 2019 $63.38K
Net Income Q1 2020 · Mar 31, 2020 −$149.76K
Net Income Q1 2020 · Mar 31, 2019 −$226.37K
Operating Income Q1 2020 · Mar 31, 2020 −$152.88K
Operating Income Q1 2020 · Mar 31, 2019 −$242.98K